@article {HARUMA337, author = {TOMOKO HARUMA and KEIICHIRO NAKAMURA and TAKESHI NISHIDA and CHIKAKO OGAWA and TOMOYUKI KUSUMOTO and NORIKO SEKI and YUJI HIRAMATSU}, title = {Pre-treatment Neutrophil to Lymphocyte Ratio Is a Predictor of Prognosis in Endometrial Cancer}, volume = {35}, number = {1}, pages = {337--343}, year = {2015}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Inflammation and tumor immunology are important in the prognosis of various cancers. We herein investigated whether pre-treatment neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and serum cancer antigen 125 (CA125) predict recurrence and survival in patients with endometrial cancer (EC). Patients and Methods: We collected complete blood counts and clinicopathological data from medical records of 320 patients with EC; their pre-treatment NLR, PLR and CA125 were analyzed for correlations with recurrence and survival, retrospectively. Results: Disease-free survival (DFS) and overall survival (OS) rates of patients with high NLR and CA125 were significantly shorter than those for patients with low NLR and CA125 (DFS: p=0.002 and p\<0.001; OS: p\<0.001 and p\<0.001, respectively). Furthermore, NLR was also an independent predictive factor for mortality in multivariate analysis (hazard ratio (HR)=3.318; 95\% confidence interval (CI)=1.154-9.538; p=0.026). Conclusion: Pre-treatment NLR is a predictor of poor prognosis in EC.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/35/1/337}, eprint = {https://ar.iiarjournals.org/content/35/1/337.full.pdf}, journal = {Anticancer Research} }